Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance

AbbVie IncTrade
Charles Schwab Corporation Common StockTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Charles Schwab Corporation Common Stock — how do they compare? AbbVie Inc trades at $248.12 (market cap $441.94B), while Charles Schwab Corporation Common Stock trades at $107.87 (market cap $186.25B). The key difference: AbbVie Inc is far larger — about 2.4× Charles Schwab Corporation Common Stock's market cap, and AbbVie Inc pays the higher dividend (2.77%). Which is the better fit depends on your goals.

ABBVSCHW
Market Cap
$441.94B$186.25B
Sector
HealthFinancials
52-Week High
$263.58$108.02
52-Week Low
$197.38$85.35
Enterprise Value
$506.19B
Dividend Yield
2.77%1.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.

Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.

Charles Schwab Corporation Common Stock

Charles Schwab (SCHW) trades at $107.99, up 0.36% today, near its all-time high. The stock shows strong technical momentum with a bullish moving average signal, though RSI levels suggest overbought conditions. Fundamentally, Q2 2026 earnings beat expectations with EPS of $1.62 versus $1.56 expected, and revenue growth accelerated to $23.92 billion in 2025. Analyst sentiment remains positive with a 56.87% buy rating and a $122.33 consensus price target, indicating potential upside.

The outlook for SCHW is favorable given robust earnings performance and upward revenue guidance, but risks include potential market volatility from economic data and ongoing litigation. Institutional buying and a high ROE of 22.45% support the bullish case, though investors should monitor inflation reports and insider selling activity for near-term cues.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About Charles Schwab Corporation Common Stock

Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.

Read more on SCHW